
Sharon X. Wen
Examiner (ID: 11379, Phone: (571)270-3064 , Office: P/1644 )
| Most Active Art Unit | 1644 |
| Art Unit(s) | 1609, 1644, 1641 |
| Total Applications | 952 |
| Issued Applications | 502 |
| Pending Applications | 90 |
| Abandoned Applications | 383 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19910274
[patent_doc_number] => 12286470
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-29
[patent_title] => Methods of determining the function of polyubiquitin using anti-polyubiquitin antibodies
[patent_app_type] => utility
[patent_app_number] => 18/159728
[patent_app_country] => US
[patent_app_date] => 2023-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 43102
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 960
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18159728
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/159728 | Methods of determining the function of polyubiquitin using anti-polyubiquitin antibodies | Jan 25, 2023 | Issued |
Array
(
[id] => 18844543
[patent_doc_number] => 20230406947
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/094151
[patent_app_country] => US
[patent_app_date] => 2023-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17015
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18094151
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/094151 | LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT | Jan 5, 2023 | Pending |
Array
(
[id] => 18971933
[patent_doc_number] => 20240052025
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => PRECISION MEDICINE FOR CHOLESTEROL TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/060185
[patent_app_country] => US
[patent_app_date] => 2022-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82419
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060185
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/060185 | PRECISION MEDICINE FOR CHOLESTEROL TREATMENT | Nov 29, 2022 | Pending |
Array
(
[id] => 18649529
[patent_doc_number] => 20230295345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/058843
[patent_app_country] => US
[patent_app_date] => 2022-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 702
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058843
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/058843 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | Nov 24, 2022 | Pending |
Array
(
[id] => 18468875
[patent_doc_number] => 20230203158
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => METHODS FOR MODULATING INTESTINE CELLS OR TISSUE FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/055992
[patent_app_country] => US
[patent_app_date] => 2022-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60389
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 220
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055992
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/055992 | METHODS FOR MODULATING INTESTINE CELLS OR TISSUE FUNCTION | Nov 15, 2022 | Abandoned |
Array
(
[id] => 18649528
[patent_doc_number] => 20230295344
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS
[patent_app_type] => utility
[patent_app_number] => 17/984611
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17984611
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | Nov 9, 2022 | Pending |
Array
(
[id] => 18597320
[patent_doc_number] => 20230272115
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING DONOR OLIGONUCLEOTIDE-BASED GENE EDITING
[patent_app_type] => utility
[patent_app_number] => 18/054080
[patent_app_country] => US
[patent_app_date] => 2022-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23455
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054080
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054080 | COMPOSITIONS AND METHODS FOR ENHANCING DONOR OLIGONUCLEOTIDE-BASED GENE EDITING | Nov 8, 2022 | Abandoned |
Array
(
[id] => 18610942
[patent_doc_number] => 20230277672
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/052360
[patent_app_country] => US
[patent_app_date] => 2022-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23736
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052360
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052360 | METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS | Nov 2, 2022 | Abandoned |
Array
(
[id] => 19170921
[patent_doc_number] => 20240156895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/976613
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27844
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17976613
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/976613 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | Oct 27, 2022 | Abandoned |
Array
(
[id] => 18938212
[patent_doc_number] => 20240033351
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
[patent_app_type] => utility
[patent_app_number] => 18/045313
[patent_app_country] => US
[patent_app_date] => 2022-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045313
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045313 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | Oct 9, 2022 | Abandoned |
Array
(
[id] => 20329750
[patent_doc_number] => 12460016
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Plasma kallikrein binding proteins
[patent_app_type] => utility
[patent_app_number] => 17/937795
[patent_app_country] => US
[patent_app_date] => 2022-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 60523
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 3158
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937795
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/937795 | Plasma kallikrein binding proteins | Oct 3, 2022 | Issued |
Array
(
[id] => 18861973
[patent_doc_number] => 20230416409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => ANTI-CERAMIDE ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/887952
[patent_app_country] => US
[patent_app_date] => 2022-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17887952
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/887952 | ANTI-CERAMIDE ANTIBODIES | Aug 14, 2022 | Abandoned |
Array
(
[id] => 18270653
[patent_doc_number] => 20230091895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => NANOBODY FOR PCSK9 AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/818631
[patent_app_country] => US
[patent_app_date] => 2022-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818631
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/818631 | NANOBODY FOR PCSK9 AND APPLICATION THEREOF | Aug 8, 2022 | Pending |
Array
(
[id] => 18531121
[patent_doc_number] => 20230236192
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => ANTI-HEPSIN ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/817539
[patent_app_country] => US
[patent_app_date] => 2022-08-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23180
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817539
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/817539 | ANTI-HEPSIN ANTIBODIES AND USES THEREOF | Aug 3, 2022 | Pending |
Array
(
[id] => 18299744
[patent_doc_number] => 20230109430
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => HUMAN TARGETS
[patent_app_type] => utility
[patent_app_number] => 17/875720
[patent_app_country] => US
[patent_app_date] => 2022-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17875720
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/875720 | HUMAN TARGETS | Jul 27, 2022 | Abandoned |
Array
(
[id] => 18187570
[patent_doc_number] => 11578139
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-02-14
[patent_title] => Antibodies against ENPP3 and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/815353
[patent_app_country] => US
[patent_app_date] => 2022-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 14
[patent_no_of_words] => 17393
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815353
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815353 | Antibodies against ENPP3 and uses thereof | Jul 26, 2022 | Issued |
Array
(
[id] => 18227062
[patent_doc_number] => 20230066056
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => METHODS AND USES FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/854808
[patent_app_country] => US
[patent_app_date] => 2022-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17854808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/854808 | METHODS AND USES FOR PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS | Jun 29, 2022 | Abandoned |
Array
(
[id] => 18309031
[patent_doc_number] => 20230112931
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => PLASMA KALLIKREIN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/842999
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17842999
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/842999 | PLASMA KALLIKREIN BINDING PROTEINS | Jun 16, 2022 | Abandoned |
Array
(
[id] => 18148874
[patent_doc_number] => 20230022731
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => ENGINEERED ANTIBODIES AND METHODS OF TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/841326
[patent_app_country] => US
[patent_app_date] => 2022-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841326
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/841326 | ENGINEERED ANTIBODIES AND METHODS OF TREATMENT | Jun 14, 2022 | Pending |
Array
(
[id] => 18077438
[patent_doc_number] => 20220403050
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/836862
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46265
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836862
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836862 | Antigen binding molecules specific for an anti-CD19 scFV | Jun 8, 2022 | Issued |